Skip to content

Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis

Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03634787
Acronym
DIAGNON
Enrollment
280
Registered
2018-08-16
Start date
2017-10-20
Completion date
2021-12-30
Last updated
2018-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Keywords

Heat Shock Proteins, early diagnosis

Brief summary

To investigate the role of Heat Shock Proteins in the mechanism of acute severe pancreatitis. In addition to test the potential treatment target of acute pancreatitis. All patients who present with clinical symptoms of acute pancreatitis are evaluated for the enrollment of the study.

Detailed description

All patients with acute pancreatitis are evaluated according to modified Atlanta classification acute pancreatitis severity scores. Blood serum, urine and DNA samples are collected from all patients presented on admission, after 24 hours, 48 hours, 72 hours. CT is performed in al patients to evaluate necrosis of pancreas Day 5-7 since hospital admission. If necrosis is not present follow-up is stopped.

Interventions

DIAGNOSTIC_TESTCT Scan Day 5-7

Computed Tomography on Day 5-7 according to a clinical protocol.

Sponsors

Vilnius University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

* no prior diagnosis of acute pancreatitis * admission to the hospital within 2 days since the clinical symptoms * confirmed diagnosis of acute pancreatitis

Exclusion criteria

* chronic pancreatitis * pancreatic cancer

Design outcomes

Primary

MeasureTime frameDescription
To measure the levels of heat shock proteins in serum and plasma in acute severe pancreatitis settings2 yearsDifferent molecular weight Heat Shock proteins role while developing acute pancreatitis.

Secondary

MeasureTime frameDescription
To measure pancreas cells activity while applying Heat Shock Protein inhibitors2 yearsTo establish a mechanism explaining the potential use of heat shock proteins inhibitors/ activators for treatment of acute pancreatitis

Countries

Lithuania

Contacts

Primary ContactKestutis Strupas, Prof. MD/PhD
kestutis.strupas@santa.lt+37052365000
Backup ContactAiste Gulla, MD
aiste.kielaite-gulla@santa.lt+37052365000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026